CANY
KNSA icon

Caxton Associates (New York)’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Caxton Associates (New York)’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-66,055
Closed -$990K – 568
2022
Q4 		$990K Buy
+66,055
New +$962K 0.07% 115

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Caxton Associates (New York)'s KNSA Position: Q1 2023 in Review

Caxton Associates (New York) sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2023, closing a stake of 66,055 shares — an estimated $990K sold.

Caxton Associates (New York) first reported a position in KNSA in Q4 2022 and held it in 1 quarter. The position peaked at $990K in Q4 2022. 132 funds tracked by Wall St. Rank hold KNSA as of Q1 2023.

  • Caxton Associates (New York) reported no remaining Kiniksa Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 66,055 Kiniksa Pharmaceuticals shares in Q1 2023, an estimated $990K.
  • Caxton Associates (New York) first reported a position in Kiniksa Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Caxton Associates (New York)'s Kiniksa Pharmaceuticals position peaked at $990K in Q4 2022.
  • 132 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2023.

Based on Caxton Associates (New York)'s 13F filing for Q1 2023, filed 15 May 2023.